<?npg-journal-abbreviation?>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NPGSJ//DTD full length article DTD version 7.0 XML//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ajarticle_v7_x.dtd?>
<?SourceDTD.Version 7.0?>
<?ConverterInfo.XSLTName naturesa2nlmx2.xsl?>
<?ConverterInfo.Version 2?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Cell Death Differ</journal-id>
    <journal-id journal-id-type="iso-abbrev">Cell Death Differ</journal-id>
    <journal-title-group>
      <journal-title>Cell Death and Differentiation</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1350-9047</issn>
    <issn pub-type="epub">1476-5403</issn>
    <publisher>
      <publisher-name>Nature Publishing Group</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">4832110</article-id>
    <article-id pub-id-type="pii">cdd201612</article-id>
    <article-id pub-id-type="doi">10.1038/cdd.2016.12</article-id>
    <article-id pub-id-type="pmid">26915292</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Correspondence</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SynTarget: an online tool to test the synergetic effect of genes on survival outcome in cancer</article-title>
      <alt-title alt-title-type="running">Correspondence</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Amelio</surname>
          <given-names>I</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tsvetkov</surname>
          <given-names>P O</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">2</xref>
        <xref ref-type="aff" rid="aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Knight</surname>
          <given-names>R A</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lisitsa</surname>
          <given-names>A</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Melino</surname>
          <given-names>G</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">1</xref>
        <xref ref-type="aff" rid="aff5">5</xref>
        <xref ref-type="aff" rid="aff6">6</xref>
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9428-5972</contrib-id>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Antonov</surname>
          <given-names>A V</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">1</xref>
        <xref ref-type="aff" rid="aff6">6</xref>
        <xref ref-type="corresp" rid="caf1">*</xref>
      </contrib>
      <aff id="aff1"><label>1</label><institution>Medical Research Council, Toxicology Unit, Leicester University</institution>, Lancaster Road, P.O. Box 138, Leicester, <country>UK</country></aff>
      <aff id="aff2"><label>2</label><institution>Aix-Marseille Université, Inserm</institution>, CRO2 UMR S 911, Faculté de Pharmacie, Marseille, <country>France</country></aff>
      <aff id="aff3"><label>3</label><institution>Institute of General Pathology and Pathophysiology, RAMS</institution>, 125315 Moscow, <country>Russia</country></aff>
      <aff id="aff4"><label>4</label><institution>Institute of Biomedical Chemistry, Russian Academy of Medical Sciences</institution>, Pogodinskaya Street, Moscow, <country>Russia</country></aff>
      <aff id="aff5"><label>5</label><institution>Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata"</institution>, Via Montpellier 1, 00133 Rome, <country>Italy</country></aff>
      <aff id="aff6"><label>6</label><institution>Institute of Cytology</institution>, Saint-Petersburg 194064, <country>Russia</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="caf1"><label>*</label><institution>Medical Research Council, Toxicology Unit, Leicester University</institution>, Hodgkin Building, Lancaster Road, P.O. Box 138, Leicester LE1 9HN, Leicestershire, <country>UK</country>. Tel: +44 (0)116 252 5562; Fax: +44 (0)116 252 5598; E-mail: <email>aa668@le.ac.uk</email></corresp>
    </author-notes>
    <pub-date pub-type="ppub">
      <month>05</month>
      <year>2016</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>26</day>
      <month>02</month>
      <year>2016</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>1</day>
      <month>5</month>
      <year>2016</year>
    </pub-date>
    <volume>23</volume>
    <issue>5</issue>
    <fpage>912</fpage>
    <lpage>912</lpage>
    <permissions>
      <copyright-statement>Copyright © 2016 Macmillan Publishers Limited</copyright-statement>
      <copyright-year>2016</copyright-year>
      <copyright-holder>Macmillan Publishers Limited</copyright-holder>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">
        <!--author-paid-->
        <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link></license-p>
      </license>
    </permissions>
  </article-meta>
</front>
<body>
  <p><italic>Dear Editor</italic>,</p>
  <p>The identification of target combinations with synergistic effects on cancer is at the leading edge of modern cancer research, especially for the development of combined anticancer therapies.<sup><xref ref-type="bibr" rid="bib1">1</xref></sup> However, at present, the basis for selection of beneficial target combinations commonly relies on expert opinion without any systematic rationale. The development of high-throughput technologies has led to the availability of large-scale clinical gene expression data sets.<sup><xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref></sup> Mining of these data sets for identification of gene combinations with synergetic effects on survival outcome in cancer could provide a systematic rationale for the identification of target combinations with potential therapeutic synergy.</p>
  <p>Multiple online tools have been developed recently to assess the relationship between expression of a single gene and clinical outcome across a variety of cancers.<sup><xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref></sup> Here we present <italic>SynTarget</italic>, the first tool able to test the cumulative effect of two genes on survival outcome and, therefore, can identify gene pairs with <italic>synergistic</italic> effects. At present, <italic>SynTarget</italic> is based on 15 large-scale gene expression data sets covering eight different cancers with the possibility to select clinically important subtypes (i.e., triple-negative, p53 mutated cancers, K-ras mutated cancers etc.). On submission, the user selects a specific cancer data set and subtype and specifies two genes. Patients in the selected data set (subtype) are split into four groups with respect to the expression of the specified genes (high−high, high−low, low−high and low−low). Next, each group is tested <italic>versus</italic> other samples to find any statistical differences in survival outcome (i.e., high−high <italic>versus</italic> others, high−low <italic>versus</italic> others and so on). This information is accompanied by individual-gene survival effects in order to understand the degree of gene synergy.</p>
  <p>Among other drug classes, immunotherapeutic agents have enormous potential for synergistic combinations.<sup><xref ref-type="bibr" rid="bib1">1</xref></sup> Triple-negative breast cancer is the subtype with the worst prognosis among all breast cancer subtypes, with currently no known molecular targets.<sup><xref ref-type="bibr" rid="bib7">7</xref></sup> We used <italic>SynTarget</italic> to search cell surface genes with the synergistic potential on survival, whose high expression leads to significantly negative prognosis. For example, ADAM9 is a membrane-anchored protein and has been implicated in a variety of biological processes, as well as being involved in cancer metastasis. RC3H2 is a membrane-associated nucleic acid-binding protein. High expression of both genes individually was slightly negatively associated (<italic>P</italic>-values ~0.07 and 0.04) with survival in triple-negative patients from the METABRIC data set.<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> The subgroup of triple-negative patients where both genes are highly expressed has a significantly negative shift (<italic>P</italic>-value&lt;6e−05) in survival, in comparison with other patients (see <xref ref-type="supplementary-material" rid="sup1">Supplementary Materials</xref> for details). Therefore, <italic>SynTarget</italic> provides statistical evidence that high expression of both RC3H2 and ADAM9 synergistically affects survival of patients with triple-negative breast cancer.</p>
  <p>In summary, <italic>SynTarget</italic> supports the need of biomedical researchers to estimate the synergy of gene expression on survival of cancer patients. To our knowledge this is a first tool of this kind and, as shown by several examples (see <xref ref-type="supplementary-material" rid="sup1">Supplementary Materials</xref>), <italic>SynTarget</italic> can be used for fast validation of the clinical synergy for two genes. <italic>SynTarget</italic> is incorporated into BioProfiling.de, an analytical portal for high-throughput cell biology,<sup><xref ref-type="bibr" rid="bib8">8</xref></sup> and is freely available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.bioprofiling.de/synergy2G">http://www.bioprofiling.de/synergy2G</ext-link>.</p>
</body>
<back>
  <ack>
    <p>This work was supported by the UK Medical Research Council (MRC) and fundamental research program of the Russian State Academies of Sciences.</p>
  </ack>
  <fn-group>
    <fn>
      <p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies this paper on Cell Death and Differentiation website (http://www.nature.com/cdd)</p>
    </fn>
  </fn-group>
  <notes>
    <p>The authors declare no conflict of interest.</p>
  </notes>
  <ref-list>
    <ref id="bib1">
      <mixed-citation publication-type="other">Melero I et al. <source>Nat Rev Cancer</source>
<year>2015</year>; <volume>15</volume>: <fpage>457</fpage>–472.<pub-id pub-id-type="pmid">26205340</pub-id></mixed-citation>
    </ref>
    <ref id="bib2">
      <mixed-citation publication-type="other">Cancer Genome Atlas Network<source>Nature</source>
<year>2012</year>; <volume>487</volume>: <fpage>330</fpage>–337.<pub-id pub-id-type="pmid">22810696</pub-id></mixed-citation>
    </ref>
    <ref id="bib3">
      <mixed-citation publication-type="other">Curtis C et al. <source>Nature</source>
<year>2012</year>; <volume>486</volume>: <fpage>346</fpage>–352.<pub-id pub-id-type="pmid">22522925</pub-id></mixed-citation>
    </ref>
    <ref id="bib4">
      <mixed-citation publication-type="other">Amelio I et al. <source>Cell Death Dis</source>
<year>2014</year>; <volume>5</volume>: <fpage>e1051</fpage>.<pub-id pub-id-type="pmid">24503543</pub-id></mixed-citation>
    </ref>
    <ref id="bib5">
      <mixed-citation publication-type="other">Antonov AV et al. <source>Oncogene</source>
<year>2014</year>; <volume>33</volume>: <fpage>1621</fpage>–1628.<pub-id pub-id-type="pmid">23686313</pub-id></mixed-citation>
    </ref>
    <ref id="bib6">
      <mixed-citation publication-type="other">Gyorffy B et al. <source>Breast Cancer Res Treat</source>
<year>2010</year>; <volume>123</volume>: <fpage>725</fpage>–731.<pub-id pub-id-type="pmid">20020197</pub-id></mixed-citation>
    </ref>
    <ref id="bib7">
      <mixed-citation publication-type="other">Crown J, O'Shaughnessy J, Gulio G. <source>Ann Oncol</source>
<year>2012</year>; <volume>23</volume>: <fpage>vi56</fpage>–vi65.<pub-id pub-id-type="pmid">23012305</pub-id></mixed-citation>
    </ref>
    <ref id="bib8">
      <mixed-citation publication-type="other">Antonov AV. <source>Nucleic Acids Res</source>
<year>2011</year>; <volume>39</volume>: <fpage>W323</fpage>–W327.<pub-id pub-id-type="pmid">21609949</pub-id></mixed-citation>
    </ref>
  </ref-list>
  <sec sec-type="supplementary-material" id="sup1">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="xob1">
      <label>Supplementary Information</label>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cdd201612x1.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</back>
